跳至主要内容
临床试验/NCT06549218
NCT06549218招募中不适用

Shortening the Path to Rare Disease Diagnosis by Using Newborn Genetic Screening and Digital Technologies (SCREEN4CARE): Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project

University Hospital Freiburg14 个研究点 分布在 3 个国家目标入组 20,000 人开始时间: 2024年12月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20,000
试验地点
14
主要终点
Whole Genome Sequencing

研究概览

简要总结

The main objective of the genetic newborn screening part of the Screen4Care-project is to shorten the path to rare disease diagnosis and to facilitate early intervention. Therefore, genetic newborn screening for currently treatable rare diseases (TREAT-panel approach) will be offered to families expecting a baby. Whole genome sequencing (WGS) will be offered as additional diagnostic approach to newborns participating in Screen4Care TREAT-panel approach, if they develop symptoms suggestive of a genetic disease.

To evaluate to what extend genetic newborn screening has an impact on participating infants and their families, a follow-up with standardised questionnaires will be performed for all participating families.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
— 至 2 Years(Child)
性别
All
接受健康志愿者

入选标准

  • TREAT-panel:
  • Infants born in one of the participating hospitals and birth centres
  • Informed consent signed by both parents/legal guardian to participate in genetic newborn screening (TREAT-panel)
  • Whole genome sequencing:
  • Participation in the TREAT-panel study
  • Symptoms suggestive of a genetic disease within the first 2 years of life
  • Informed consent signed by both parents/legal guardian to participate in genetic newborn screening (TREAT-panel) and the whole genome sequencing

排除标准

  • Missing informed consent of parents/legal guardian

研究组 & 干预措施

newborn screening

Other

All newborns participating in the study will receive a genetic newborn screening for predefined treatable diseases. Newborns participating in the TREAT-panel developing symptoms suggestive of a genetic disease during the first 2 years of life can receive whole genome sequencing.

干预措施: newborn genetic screening and whole genome sequencing (Diagnostic Test)

结局指标

主要结局

Whole Genome Sequencing

时间窗: 2 years

• Percentage of symptomatic patients whom parents will accept to be enrolled in whole genome sequencing

TREAT-panel

时间窗: 1 year

• Percentage of eligible couples who will accept to participate to the genetic newborn screening

次要结局

  • TREAT-panel(1 year)
  • Whole Genome Sequencing(2 years)

研究者

发起方
University Hospital Freiburg
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jan Kirschner

Prof. Dr.

University Hospital Freiburg

研究点 (14)

Loading locations...

相似试验